决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell.
结果表明,带有长间隔区的第三代抗VEGFR2纳米抗体CAR T细胞具有更优的功能,可能成为实体瘤治疗更好的候选方案。
表达嵌合抗原受体的 T(CAR-T)细胞用于癌症免疫治疗已获得相当大的临床重要性。CAR-T 细胞需要优化的细胞内信号结构域才能适当激活,而为了正确识别抗原,细胞外间隔区的长度和组成是关键因素。
我们构建了两种第三代基于纳米抗体的VEGFR2-CAR,分别含有IgG1 hinge-CH2-CH3区域或仅hinge作为长或短胞外间隔区。这两种CAR还包含CD28、OX40和CD3的胞内激活结构域。来自健康个体的T细胞被这两种CAR高效转导,并在遇到VEGFR2+细胞后表现出IL-2和IFN-细胞因子分泌增加,以及CD69和CD25激活标志物和细胞溶解活性。携带长间隔区的VEGFR2-CAR T细胞显示出更高的细胞因子释放和CD69及CD25表达,此外对VEGFR2+靶细胞具有更有效的细胞溶解作用。
BACKGROUND: The chimeric antigen receptor-expressing T (CAR-T) cells for cancer immunotherapy have obtained considerable clinical importance. CAR T cells need an optimized intracellular signaling domain to get appropriately activated and also for the proper antigen recognition, the length and composition of the extracellular spacer are critical factors. RESULTS: We constructed two third-generation nanobody-based VEGFR2-CARs containing either IgG1 hinge-CH2-CH3 region or hinge-only as long or short extracellular spacers, respectively. Both CARs also contained intracellular activating domains of CD28, OX40, and CD3 . The T cells from healthy individuals were transduced efficiently with the two CARs, and showed increased secretion of IL-2 and IFN- cytokines, and also CD69 and CD25 activation markers along with cytolytic activity after encountering VEGFR2 + cells. The VEGFR2-CAR T cells harboring the long spacer showed higher cytokine release and CD69 and CD25 expression in addition to a more efficient cytolytic effect on VEGFR2 + target cells. CONCLUSIONS: The results demonstrated that the third-generation anti-VEGFR2 nanobody-based CAR T cell with a long spacer had a superior function and potentially could be a better candidate for solid tumor treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。